Retrospective Cohort Study on the Risk of Venous Thromboembolism with the use of combined oral contraceptives containing Chlormadinone Acetate/Ethinylestradiol and Levonorgestrel/Ethinylestradiol (RIVET-RCS)

First published 14/04/2016

Last updated 10/06/2024

EU PAS number:

EUPAS12171

Study

Finalised

Download as PDF

Documents

Study protocol

Study results

Study report

Other information

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

This study has been awarded the ENCePP seal

Conflicts of interest of investigators

Annex5_Declaration of interest _RivetCC_2016

English (921.51 KB - PDF)View document

Composition of steering group and observers

SMAC_RIVET-CC_2016-04-14

English (220.04 KB - PDF)View document

Signed code of conduct

2016-0039-DoC CoC-SDPP-12171

English (65.32 KB - PDF)View document

Signed code of conduct checklist

2016-0039-Checklist CoC-SDPP-12171

English (279.16 KB - PDF)View document

Signed checklist for study protocols

2016-0039-Checklist Protocol-SDPP-12171

English (399.88 KB - PDF)View document

Retrospective Cohort Study on the Risk of Venous Thromboembolism with the use of combined oral contraceptives containing Chlormadinone Acetate/Ethinylestradiol and Levonorgestrel/Ethinylestradiol (RIVET-RCS)

Secondary tabs

Share this page